Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Pain
Interventions: Codeine Sulfate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hyperglycemia, Diabetes Mellitus
Interventions: Lantus® (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Cardiovascular Diseases
Interventions: Lipid Challenge; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ovarian Cancer
Interventions: TUB-040 + Carbo + BEV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • East Brunswick, New Jersey • New York, New York

Conditions: Type 1 Diabetes
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Healthy
Interventions: Inosine; Drug
Lead sponsor: Michael Alan Schwarzschild; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: MK-8591A, Islatravir, Doravine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obstructive Sleep Apnea
Interventions: AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more

Conditions: Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Interventions: Colchicine, Diltiazem ER; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: GDC-0134 F09 Formulation, GDC-0134 F15 Formulation, GDC-0134 F16 Formulation; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Blood Pressure, Neurovascular Control
Interventions: Time-Restricted Feeding; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Food Selection
Interventions: Control (QR) Labels, Low Environmental Harm Labels, High Environmental Harm Labels, Environmental Harm Traffic Light Labels, Environmental Grade Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Malignancies
Interventions: MGCD265; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity
Interventions: Liraglutide, Oral Semaglutide, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cypress, California

Conditions: Gastrointestinal Irritation
Interventions: My Nutritional Health App; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overweight
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 0 Years to 39 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: PF-04447943; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Myeloid Leukemia
Interventions: CPX-351, Venetoclax, Midostaurin, Enasidenib; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Duarte, California • Palo Alto, California • Augusta, Georgia + 7 more

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablet; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anxiety Disorders
Interventions: LY2456302; Drug
Lead sponsor: Andrew Krystal; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pre-diabetes
Interventions: Vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions

Lantus in Prediabetes

Lipid Challenge in Adults

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

To Evaluate the Bioavailability of a Tablet of AZD1656

Open Label Extension Study of HT-100 in Patients With DMD

A Food-Drug Interaction Study of Serum Urate After Oral Inosine

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Crossover Trial of AD109 in Obstructive Sleep Apnea

Drug-Drug Interaction Study Between Colchicine and Diltiazem ER

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Meal Timing and Blood Pressure

Testing Non-Nutrition Menu Labels on Food Selections

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

My Nutritional Health App Testing

Time to Eat Study - Pilot

The Early and Late Contribution of Fasting and Postprandial Triglycerides on Newborn Subcutaneous and Intrahepatic Fat in Pregnancy

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions

FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes